
## Venkatesh Rajamanickam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/892336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications, 2021, 12, 1047.	12.8	96
2	Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncolmmunology, 2021, 10, 1900635.	4.6	73
3	Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell, 2022, 40, 410-423.e7.	16.8	47
4	Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling. British Journal of Cancer, 2020, 123, 1326-1335.	6.4	39
5	PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors. Journal of Clinical Investigation, 2022, 132, .	8.2	37
6	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	3.5	30
7	Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. PLoS ONE, 2020, 15, e0238380.	2.5	16
8	Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. Cancer Immunology Research, 2021, 9, 415-429.	3.4	11
9	microRNA alterations in ALDH positive mammary epithelial cells: a crucial contributing factor towards breast cancer risk reduction in case of early pregnancy. BMC Cancer, 2014, 14, 644.	2.6	10
10	Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at <i>12q15</i> . Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 644-652.	2.5	9
11	Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Research, 2016, 76, 1916-1925.	0.9	7
12	A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 1595-1605.	7.0	7
13	A Breast Tissue Protein Expression Profile Contributing to Early Parity-Induced Protection Against Breast Cancer. Cellular Physiology and Biochemistry, 2015, 37, 1671-1685.	1.6	6
14	The serum protein profile of early parity which induces protection against breast cancer. Oncotarget, 2016, 7, 82538-82553.	1.8	5
15	Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens. Cancer Immunology Research, 2021, 9, 602-611.	3.4	4
16	miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 710337.	2.8	3
17	Abstract 3267: Targeted DNA and RNA sequencing identifies breast cancer risk variants associated with differential expression of CASP8 and CFLAR/CASP10. Cancer Research, 2014, 74, 3267-3267.	0.9	1
18	Disruption of the SUMO Pathway in a High-Risk B-Cell Non-Hodgkin Lymphoma Pedigree. Blood, 2015, 126, 2682-2682.	1.4	0

0

#	Article	IF	CITATIONS
19	Abstract P6-05-08: Progesterone receptor membrane component 1 controls cellular proliferation and plays a key role in the molecular circuitry of both ER positive and triple negative breast cancers. , 2020, , .		Ο
	Abstract 270G. Comprehensive immune profiling of primery types infiltrating hyperboxites isolated		

Abstract 2706: Comprehensive immune profiling of primary tumor-infiltrating lymphocytes isolated from primary non-small cell lung cancer specimens. , 2019, , .